Jennifer A Domm, MD | Pediatric ...

Dr. Jennifer A. Domm

Claim this profile

The Children's Hospital at TriStar Centennial

Expert in Uterine Tumors
Expert in Cancer
52 reported clinical trials
104 drugs studied

About Jennifer A. Domm

Education:

  • Obtained MD from the University of Tennessee Health Science Center, Memphis, TN.
  • Completed Residency in Pediatrics at Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN.
  • Undertook Fellowship in Pediatric Critical Care Medicine at Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN.

Experience:

  • Board-certified in Pediatrics and Pediatric Critical Care Medicine.
  • Associated with The Children's Hospital at TriStar Centennial.

Area of expertise

1Uterine Tumors
Global Leader
Jennifer A. Domm has run 21 trials for Uterine Tumors. Some of their research focus areas include:
Stage I
Stage IV
Stage II
2Cancer
Global Leader
Jennifer A. Domm has run 18 trials for Cancer. Some of their research focus areas include:
Stage I
Stage IV
Stage II

Affiliated Hospitals

Image of trial facility.
The Children's Hospital At TriStar Centennial

Clinical Trials Jennifer A. Domm is currently running

Image of trial facility.

Inotuzumab Ozogamicin

for Acute Lymphoblastic Leukemia

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
Image of trial facility.

DAY101

for Langerhans Cell Histiocytosis

This trial tests the safety and effectiveness of tovorafenib (DAY101) in children and young adults with Langerhans cell histiocytosis that is worsening, has returned, or does not respond to other treatments. Tovorafenib is taken orally and works by blocking enzymes needed for cancer cell growth. The study aims to find the best dose and observe the response and side effects over time.
Recruiting1 award Phase 228 criteria

More about Jennifer A. Domm

Clinical Trial Related5 years of experience running clinical trials · Led 52 trials as a Principal Investigator · 18 Active Clinical Trials
Treatments Jennifer A. Domm has experience with
  • Cyclophosphamide
  • Radiation Therapy
  • Etoposide
  • Cisplatin
  • Carboplatin
  • Doxorubicin Hydrochloride

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jennifer A. Domm specialize in?
Jennifer A. Domm focuses on Uterine Tumors and Cancer. In particular, much of their work with Uterine Tumors has involved Stage I patients, or patients who are Stage IV.
Is Jennifer A. Domm currently recruiting for clinical trials?
Yes, Jennifer A. Domm is currently recruiting for 17 clinical trials in Nashville Tennessee. If you're interested in participating, you should apply.
Are there any treatments that Jennifer A. Domm has studied deeply?
Yes, Jennifer A. Domm has studied treatments such as Cyclophosphamide, Radiation Therapy, Etoposide.
What is the best way to schedule an appointment with Jennifer A. Domm?
Apply for one of the trials that Jennifer A. Domm is conducting.
What is the office address of Jennifer A. Domm?
The office of Jennifer A. Domm is located at: The Children's Hospital at TriStar Centennial, Nashville, Tennessee 37203 United States. This is the address for their practice at the The Children's Hospital at TriStar Centennial.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security